Cinical trial data and guidelines on optimal first-line regimens for metastatic KRAS mutated lung adenocarcinoma.
Case: A 64-year-old male diagnosed with a KRAS G12C mutated stage IV adenocarcinoma
Clinical Presentation:
Initial Clinical Workup and Diagnosis:
Initial Treatments:
Disease Progression and Subsequent Treatments:
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
April 26th 2024During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More